Cargando…
Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments
BACKGROUND: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patient...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842185/ https://www.ncbi.nlm.nih.gov/pubmed/33520724 http://dx.doi.org/10.3389/fonc.2020.613089 |
_version_ | 1783643961375588352 |
---|---|
author | Doyen, Jérôme Sunyach, Marie-Pierre Almairac, Fabien Bourg, Véronique Naghavi, Arash O. Duhil de Bénazé, Gwenaëlle Claren, Audrey Padovani, Laetitia Benezery, Karen Noël, Georges Hannoun-Lévi, Jean-Michel Guedea, Ferran Giralt, Jordi Vidal, Marie Baudin, Guillaume Opitz, Lucas Claude, Line Bondiau, Pierre-Yves |
author_facet | Doyen, Jérôme Sunyach, Marie-Pierre Almairac, Fabien Bourg, Véronique Naghavi, Arash O. Duhil de Bénazé, Gwenaëlle Claren, Audrey Padovani, Laetitia Benezery, Karen Noël, Georges Hannoun-Lévi, Jean-Michel Guedea, Ferran Giralt, Jordi Vidal, Marie Baudin, Guillaume Opitz, Lucas Claude, Line Bondiau, Pierre-Yves |
author_sort | Doyen, Jérôme |
collection | PubMed |
description | BACKGROUND: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patients irradiated with high dose rate pulsed proton therapy (PT). MATERIALS AND METHODS: A single institution retrospective chart review was performed for patients treated with high dose rate (10 Gy per second) pulsed proton therapy, from September 2016 to April 2020. This included both benign and malignant tumors with ≥3 months follow-up, evaluated for acute (≤2 months) and subacute (>2 months) toxicity after the completion of PT. RESULTS: There were 127 patients identified, with a median follow up of 14.8 months (3–42.9 months). The median age was 55 years (1.6–89). The cohort most commonly consisted of benign disease (55.1%), cranial targets (95.1%), and were treated with surgery prior to PT (56.7%). There was a median total PT dose of 56 Gy (30–74 Gy), dose per fraction of 2 Gy (1–3 Gy), and CTV size of 47.6 ml (5.6–2,106.1 ml). Maximum acute grade ≥2 toxicity were observed in 49 (38.6%) patients, of which 8 (6.3%) experienced grade 3 toxicity. No acute grade 4 or 5 toxicity was observed. Maximum subacute grade 2, 3, and 4 toxicity were discovered in 25 (19.7%), 12 (9.4%), and 1 (0.8%) patient(s), respectively. CONCLUSION: In this cohort, utilizing high dose rate proton therapy (10 Gy per second) did not result in a major decrease in acute and subacute toxicity. Longer follow-up and comparative studies with conventional dose rate are required to evaluate whether this approach offers a toxicity benefit. |
format | Online Article Text |
id | pubmed-7842185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78421852021-01-29 Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments Doyen, Jérôme Sunyach, Marie-Pierre Almairac, Fabien Bourg, Véronique Naghavi, Arash O. Duhil de Bénazé, Gwenaëlle Claren, Audrey Padovani, Laetitia Benezery, Karen Noël, Georges Hannoun-Lévi, Jean-Michel Guedea, Ferran Giralt, Jordi Vidal, Marie Baudin, Guillaume Opitz, Lucas Claude, Line Bondiau, Pierre-Yves Front Oncol Oncology BACKGROUND: The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patients irradiated with high dose rate pulsed proton therapy (PT). MATERIALS AND METHODS: A single institution retrospective chart review was performed for patients treated with high dose rate (10 Gy per second) pulsed proton therapy, from September 2016 to April 2020. This included both benign and malignant tumors with ≥3 months follow-up, evaluated for acute (≤2 months) and subacute (>2 months) toxicity after the completion of PT. RESULTS: There were 127 patients identified, with a median follow up of 14.8 months (3–42.9 months). The median age was 55 years (1.6–89). The cohort most commonly consisted of benign disease (55.1%), cranial targets (95.1%), and were treated with surgery prior to PT (56.7%). There was a median total PT dose of 56 Gy (30–74 Gy), dose per fraction of 2 Gy (1–3 Gy), and CTV size of 47.6 ml (5.6–2,106.1 ml). Maximum acute grade ≥2 toxicity were observed in 49 (38.6%) patients, of which 8 (6.3%) experienced grade 3 toxicity. No acute grade 4 or 5 toxicity was observed. Maximum subacute grade 2, 3, and 4 toxicity were discovered in 25 (19.7%), 12 (9.4%), and 1 (0.8%) patient(s), respectively. CONCLUSION: In this cohort, utilizing high dose rate proton therapy (10 Gy per second) did not result in a major decrease in acute and subacute toxicity. Longer follow-up and comparative studies with conventional dose rate are required to evaluate whether this approach offers a toxicity benefit. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7842185/ /pubmed/33520724 http://dx.doi.org/10.3389/fonc.2020.613089 Text en Copyright © 2021 Doyen, Sunyach, Almairac, Bourg, Naghavi, Duhil de Bénazé, Claren, Padovani, Benezery, Noël, Hannoun-Lévi, Guedea, Giralt, Vidal, Baudin, Opitz, Claude and Bondiau http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Doyen, Jérôme Sunyach, Marie-Pierre Almairac, Fabien Bourg, Véronique Naghavi, Arash O. Duhil de Bénazé, Gwenaëlle Claren, Audrey Padovani, Laetitia Benezery, Karen Noël, Georges Hannoun-Lévi, Jean-Michel Guedea, Ferran Giralt, Jordi Vidal, Marie Baudin, Guillaume Opitz, Lucas Claude, Line Bondiau, Pierre-Yves Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments |
title | Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments |
title_full | Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments |
title_fullStr | Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments |
title_full_unstemmed | Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments |
title_short | Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments |
title_sort | early toxicities after high dose rate proton therapy in cancer treatments |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842185/ https://www.ncbi.nlm.nih.gov/pubmed/33520724 http://dx.doi.org/10.3389/fonc.2020.613089 |
work_keys_str_mv | AT doyenjerome earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT sunyachmariepierre earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT almairacfabien earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT bourgveronique earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT naghaviarasho earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT duhildebenazegwenaelle earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT clarenaudrey earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT padovanilaetitia earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT benezerykaren earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT noelgeorges earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT hannounlevijeanmichel earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT guedeaferran earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT giraltjordi earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT vidalmarie earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT baudinguillaume earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT opitzlucas earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT claudeline earlytoxicitiesafterhighdoserateprotontherapyincancertreatments AT bondiaupierreyves earlytoxicitiesafterhighdoserateprotontherapyincancertreatments |